首页> 美国卫生研究院文献>Clinical Cosmetic and Investigational Dermatology >Keloid treatment: what about adjuvant radiotherapy?
【2h】

Keloid treatment: what about adjuvant radiotherapy?

机译:瘢痕loid治疗:辅助放疗怎么样?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Keloids are debilitating fibrous skin proliferations with a high recurrence rate after surgical treatment. Postoperative radiotherapy (PORT) is a well-tolerated adjuvant treatment to reduce the risk of recurrence, but the optimal regimen for this combined treatment remains unknown. The aim of this study is to evaluate the efficacy of combining surgical excision and immediate PORT.>Methods: We retrospectively reviewed the records of patients with keloid lesions treated with adjuvant PORT in the period 2005–2014 at Geneva University Hospitals. Main outcomes were the rates of complications and recurrence in patients with a minimal follow-up of 1 year, including the Patient and Observer Scar Assessment Scale satisfaction scores.>Results: 10 patients with 16 keloids were eligible (mean follow-up, 37 months). Only one recurrence was reported (6%). In 12.5% of cases, mild erythema appeared in the early postoperative period. No major complications were observed. The overall patient and observer satisfaction rate was excellent.>Conclusion: Surgical excision combined with immediate PORT is an effective and easy treatment with good esthetic results and an acceptable recurrence rate. It should be considered for patients with persistent keloid formation after failure of other treatments and those at high risk of relapse.
机译:>背景:瘢痕loid在手术治疗后会破坏纤维性皮肤增生,复发率很高。术后放疗(PORT)是一种耐受良好的辅助治疗,可降低复发风险,但这种联合治疗的最佳方案仍然未知。这项研究的目的是评估手术切除和即刻PORT结合的疗效。>方法:我们回顾性回顾了2005-2014年在日内瓦大学接受PORT辅助治疗的瘢痕病变患者的记录。医院。主要结局为最少随访1年的患者的并发症发生率和复发率,包括患者和观察者疤痕评估量表的满意度得分。>结果:10例16瘢痕loid患者符合条件(平均随访37个月)。据报道只有一次复发(6%)。在12.5%的病例中,术后早期出现轻度红斑。没有观察到重大并发症。患者和观察者的总体满意率非常好。>结论:外科切除结合即刻PORT是一种有效,简便的治疗方法,具有良好的美学效果和可接受的复发率。对于其他治疗失败后仍存在持续性瘢痕loid形成且复发风险高的患者,应考虑使用该药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号